Eyes are one of the most vital sensory organs and is second most complex after brain. It is a vulnerable organ with various disorders that can threaten its structure, function or both. Ophthalmology is a branch of medicine and surgery which deals with the diagnosis and treatment of eye disorders. Some of the most common eye disorders are refractive errors such as myopia, hyperopia, presbyopia, and astigmatism; glaucoma, ocular infections and inflammation such as conjunctivitis, blepharitis, keratitis; dry eye; cataract; and retinal diseases.
Treatment paradigm of eye disorders primarily aims to reduce inflammation, repairs traumatic injuries, and improves or saves eyesight. Treatment comprises of medication, surgery, prescription glasses or contact lenses and treatment of systemic conditions affecting eye. Prevalence of eye disorders has been increasing incessantly. This is expected to boost global ophthalmic market. Furthermore, other factors such as rising R&D in the industry, growing geriatric population and increasing awareness are also expected to drive growth. However, the market faces various challenges due to high cost of diagnosis & treatment, patent expiration of blockbuster ophthalmic drugs and limited insurance coverage.
The report 鈥淕lobal Ophthalmology 麻豆原创 (By Segment 鈥� Surgical & Vision Care; By Disease - Retinal Disorder, Glaucoma & Dry Eye; By Drug Class 鈥� Anti Glaucoma Drugs, Dry Eye Drugs & Anti-infective Drugs; By Region 鈥� North America, Europe & Asia Pacific) 麻豆原创 Outlook 2025鈥� provides in-depth analysis of the current scenario, detailed market outlook of the global ophthalmology market with market segmentation across indications such as Retinal Disorder, Glaucoma & Dry Eye; drug classes such as 鈥� Anti Glaucoma Drugs, Dry Eye Drugs & Anti-infective Drugs. Future forecasts of ophthalmology market overall and across various market segments has been provided in the report till 2025. Furthermore, major industry players have been prudently analysed in the competitive landscape section of the report in order to provide key comparative insights.
Major industry players operating in the global ophthalmology market include Novartis AG, Bausch & Lomb, Inc., F.Hoffman La-Roche, Regeneron Pharmaceuticals, Inc., Allergan PLC, among others. These players are profiled herein based on attributes such as business overview, product segments and financial analysis. It also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global ophthalmology market market.
Ophthalmic drug delivery has been one of the most daunting task for clinicians. With the advent of novel drug delivery techniques, unique delivery systems of drug administration has been introduced into the market. Novel dosage form mainly comprises of microemulsions, nanosuspensions, dendrimers, niosomes, liposomes etc.
The report 鈥淕lobal Ophthalmology 麻豆原创 (By Segment 鈥� Surgical & Vision Care; By Disease - Retinal Disorder, Glaucoma & Dry Eye; By Drug Class 鈥� Anti Glaucoma Drugs, Dry Eye Drugs & Anti-infective Drugs; By Region 鈥� North America, Europe & Asia Pacific) 麻豆原创 Outlook 2025鈥� provides in-depth analysis of the current scenario, detailed market outlook of the global ophthalmology market overall as well as across market segments such as by disease and by drug class for the period 2019-25. Regional analysis is done across major markets in North America, Europe and Asia Pacific.
The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities in global ophthalmology market. The report has been segmented as following:-
麻豆原创 Segmentation 鈥� Segments
鈥� Surgical
鈥� Vision Care
麻豆原创 Segmentation 鈥� Disease
鈥� Retinal Disorder
鈥� Glaucoma
鈥� Dry Eye
麻豆原创 Segmentation 鈥� Drug Class
鈥� Anti-Glaucoma Drugs
鈥� Dry Eye Drugs
鈥� Anti-Infective Drugs
Geographical Coverage
鈥� North America 鈥� The US
鈥� Europe 鈥� Germany & The UK
鈥� Asia Pacific 鈥� China & India
Key Vendors
鈥� Novartis AG
鈥� Bausch & Lomb, Inc.
鈥� F.Hoffman La-Roche
鈥� Regeneron Pharmaceuticals, Inc.
鈥� Allergan PLC
1. Executive Summary
2. Research Methodology
3. Ophthalmology
3.1 Background
3.2 Eye Disorders
4. 麻豆原创 Analysis
4.1 麻豆原创 Sizing (Actual & Forecasted)
4.2 麻豆原创 Share Analysis
4.2.1 麻豆原创 Share by Segment
4.2.2 麻豆原创 Share by Indication
4.2.3 麻豆原创 Share by Drug Class
4.2.4 麻豆原创 Share by Products
4.2.5 麻豆原创 Share by Product Type
4.2.6 麻豆原创 Share by Dosage Type
4.2.7 麻豆原创 Share by Region
5. 麻豆原创 Segmentation
5.1 Segments
5.1.1 Surgical
5.1.1.1 麻豆原创 Sizing (Actual & Forecasted)
5.1.1.2 Implantable 麻豆原创 Sizing (Actual & Forecasted)
5.1.1.3 Consumables 麻豆原创 Sizing (Actual & Forecasted)
5.1.1.3 Equipment/Others 麻豆原创 Sizing (Actual & Forecasted)
5.1.2 Vision Care
5.1.2.1 麻豆原创 Sizing (Actual & Forecasted)
5.1.2.2 Contact Lenses 麻豆原创 Sizing (Actual & Forecasted)
5.1.2.3 Contact Lenses 麻豆原创 Sizing (Actual & Forecasted)
5.2 Disease
5.2.1 Retinal Disorder
5.2.1.1 麻豆原创 Sizing (Actual & Forecasted)
5.2.1.2 麻豆原创 Share by Disease Type
5.2.1.3 nAMD 麻豆原创 Sizing (Actual & Forecasted)
5.2.1.4 DME/DR 麻豆原创 Sizing (Actual & Forecasted)
5.2.1.5 DME/DR 麻豆原创 Sizing (Actual & Forecasted)
5.2.2 Glaucoma
5.2.2.1 麻豆原创 Sizing (Actual & Forecasted)
5.2.3 Dry Eye
5.2.3.1 麻豆原创 Sizing (Actual & Forecasted)
5.3 Drug Class
5.3.1 Anti-Glaucoma Drugs
5.3.2 Dry Eye Drugs
5.3.3 Anti-Infective Drugs
6. Regional Analysis
6.1 North America
6.1.1 麻豆原创 Sizing (Actual & Forecasted)
6.1.2 The US
6.1.2.1 麻豆原创 Sizing (Actual & Forecasted)
6.1.2.2 麻豆原创 Share by Dosage Type
6.1.2.3 麻豆原创 Share by End-Users
6.2 Europe
6.2.1 麻豆原创 Sizing (Actual & Forecasted)
6.2.2 Germany
6.2.2.1 麻豆原创 Sizing (Actual & Forecasted)
6.2.3 The UK
6.2.2.1 麻豆原创 Sizing (Actual & Forecasted)
6.3 Asia Pacific
6.3.1 麻豆原创 Sizing (Actual & Forecasted)
6.3.2 China
6.3.2.1 麻豆原创 Sizing (Actual & Forecasted)
6.3.4 India
6.3.4.1 麻豆原创 Sizing (Actual & Forecasted)
6.3.4.2 麻豆原创 Share by Devices
7. 麻豆原创 Dynamics
7.1 Industry Trends & Development
7.1.1 Mergers & Acquisitions
7.1.2 Advent of Novel Drug Delivery Techniques
7.2 Growth Drivers
7.2.1 Prevalence of Eye Disorder
7.2.3 Rising R&D in the Industry
7.2.4 Growing Geriatric Population
7.2.5 Increasing Awareness
7.3 Challenges
7.3.1 High Cost of Diagnosis & Treatment
7.3.2 Patent Expiration of Blockbuster Ophthalmic Drugs
7.3.3 Limited Insurance Coverage
8. Competitive Landscape
8.1 麻豆原创 Share Analysis
8.2 Financial Analysis
9. Company Profiles
9.1 Novartis AG
9.2 Bausch & Lomb, Inc.
9.3 F.Hoffman La-Roche
9.4 Regeneron Pharmaceuticals, Inc.
9.5 Allergan PLC
List of Tables
Table 1: Analysis of Various Ocular Disorders
Table 2: Drugs Administered for Diagnosis and Treatment of Ocular Disorders
Table 3: Mergers & Acquisitions in Ophthalmic 麻豆原创
Table 4: Global Ophthalmic 麻豆原创 鈥� Revenue Forecast by Companies, FY2018-FY2022E (US$ Billions)
Table 5: Global Ophthalmic 麻豆原创 鈥� Financial Analysis of Leading Companies
Table 6: Novartis AG Ophthalmic Drugs Clinical Pipeline
Table 7: Bausch & Lomb, Inc. Number of Drugs by Indication
Table 8: Bausch & Lomb, Inc. Bausch & Lomb, Inc. Clinical Drug Pipeline
Table 9: F.Hoffman La-Roche Ophthalmic Clinical Pipeline
Table 10: Regeneron Pharmaceuticals, Inc. Ophthalmic Clinical Pipeline
Table 11: F.Hoffman La-Roche Ophthalmic Clinical Pipeline
List of Figures
Figure 1: Rockville Research 鈥� Research Methodology
Figure 2: Global Ophthalmic Drugs 麻豆原创 Size by Value, 2016-25E (US$ Billions)
Figure 3: Global Ophthalmic 麻豆原创 Share by Segment (2018)
Figure 4: Global Ophthalmic Drugs 麻豆原创 Share by Indication (2018)
Figure 5: Global Ophthalmic Drugs 麻豆原创 Share by Drug Class (2018)
Figure 6: Global Ophthalmic Devices 麻豆原创 Share by Products (2018)
Figure 7: Global Ophthalmic Drugs 麻豆原创 Share by Product Type (2081)
Figure 8: Global Ophthalmic Drugs 麻豆原创 Share by Dosage Type (2018)
Figure 9: Global Ophthalmic 麻豆原创 Share by Region (2018)
Figure 10: Global Ophthalmic Surgical Devices 麻豆原创 Size by Value, 2017-25E (US$ Billions)
Figure 11: Global Ophthalmic Surgical Devices 鈥� Implantable 麻豆原创 Size by Value, 2017-25E (US$ Billions)
Figure 12: Global Ophthalmic Surgical Devices 鈥� Consumables 麻豆原创 Size by Value, 2017-25E (US$ Billions)
Figure 13: Global Ophthalmic Surgical Devices 鈥� Equipment/Others 麻豆原创 Size by Value, 2017-25E (US$ Billions)
Figure 14: Global Ophthalmic 鈥� Vision Care 麻豆原创 Size by Value, 2017-25E (US$ Billions)
Figure 15: Global Ophthalmic Vision Care 鈥� Contact Lenses 麻豆原创 Size by Value, 2017-25E (US$ Billions)
Figure 16: Global Ophthalmic Vision Care 鈥� Ocular Health 麻豆原创 Size by Value, 2017-25E (US$ Billions)
Figure 17: Global Ophthalmic Disease 鈥� Retinal Disorder Drugs 麻豆原创 Size by Value, 2017-25E (US$ Billions)
Figure 18: Global Ophthalmic 鈥� Retinal Disorder Drugs 麻豆原创 Share by Disease Type (2018)
Figure 19: Global Ophthalmic 鈥� Retinal Disorder nAMD Drugs 麻豆原创 Size by Value, 2017-25E (US$ Billions)
Figure 20: Global Ophthalmic 鈥� Retinal Disorder DME/DR Drugs 麻豆原创 Size by Value, 2017-25E (US$ Billions)
Figure 21: Global Ophthalmic 鈥� Retinal Disorder RVO Drugs 麻豆原创 Size by Value, 2017-25E (US$ Billions)
Figure 22: Global Ophthalmic Diseases 鈥� Glaucoma Drugs 麻豆原创 Size by Value, 2017-25E (US$ Billions)
Figure 23: Global Ophthalmic Diseases 鈥� Dry Eye Drugs 麻豆原创 Size by Value, 2017-25E (US$ Billions)
Figure 24: Global Ophthalmic 麻豆原创 鈥� Anti-Infective Drugs 麻豆原创 Size by Value, 2018-25E (US$ Billions)
Figure 25: Global Ophthalmic 麻豆原创 鈥� Dry Eye Drugs 麻豆原创 Size by Value, 2018-25E (US$ Billions)
Figure 26: Global Ophthalmic 麻豆原创 鈥� Anti-Infective Drugs 麻豆原创 Size by Value, 2018-25E (US$ Billions)
Figure 27: North America Ophthalmic 麻豆原创 Size by Value, 2016-25E (US$ Billions)
Figure 28: The US Ophthalmic Drugs 麻豆原创 Size by Value, 2016-25E (US$ Billions)
Figure 29: The US Ophthalmic Drugs 麻豆原创 Share by Dosage Type (2018)
Figure 30: The US Ophthalmic lasers market share, by end-use
Figure 31: Europe Ophthalmic 麻豆原创 Size by Value, 2016-25E (US$ Billions)
Figure 32: Germany Ophthalmic 麻豆原创 Size by Value, 2016-25E (US$ Billions)
Figure 33: The UK Ophthalmic 麻豆原创 Size by Value, 2016-25E (US$ Billions)
Figure 34: Asia Pacific Ophthalmic Drugs 麻豆原创 Size by Value, 2016-25E (US$ Billions)
Figure 35: China Ophthalmic 麻豆原创 Size by Value, 2017-25E (US$ Billions)
Figure 36: India Ophthalmic 麻豆原创 Size by Value, 2017-25E (US$ Billions)
Figure 37: India Ophthalmic Devices 麻豆原创 Share by Device Type (2018)
Figure 38: Prevalence and Projections of Eye Disorders, 2017 & 2030E (Millions)
Figure 39: Global Ageing (Aged 65 years and above) Population, 2013-18 (Millions)
Figure 40: Incidence of Eye-Diseases with Age (%)
Figure 41: Global Ophthalmic Medtech 麻豆原创 Share by Companies (2018 & 2025E)
Figure 42: Global Ophthalmic Surgery 麻豆原创 Share by Companies (2018)
Figure 43: Novartis AG Revenue by Business Segment (FY2018)
Figure 44: Novartis AG Net Sales, FY2015-FY2018 (US$ Billions)
Figure 45: Bausch & Lomb, Inc. Revenue by Business Segment (FY2018)
Figure 46: Bausch & Lomb, Inc. Net Sales, FY2015-FY2018 (US$ Millions)
Figure 47: F.Hoffman La-Roche Revenue by Business Segment (FY2018)
Figure 48: F.Hoffman La-Roche Net Sales, FY2015-FY2018 (US$ Billions)
Figure 49: Regeneron Pharmaceuticals, Inc. Revenue by Business Segment (FY2018)
Figure 50: Regeneron Pharmaceuticals - EYLEA (aflibercept) Sales, FY2012-FY2018
Figure 51: Regeneron Pharmaceuticals, Inc. Net Sales, FY2015-FY2018 (US$ Billions)
Figure 52: F.Hoffman La-Roche Revenue by Business Segment (FY2018)
Figure 53: F.Hoffman La-Roche Net Sales, FY2015-FY2018 (US$ Billions)
Novartis AG
Bausch & Lomb, Inc.
F.Hoffman La-Roche
Regeneron Pharmaceuticals, Inc.
Allergan PLC
听
听
*If Applicable.